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ReviewDuring the past 50 years, the prevalence of asthma has
increased and this has coincided with our changing
relation with microorganisms. Asthma is a complex
disease associated with local tissue inflammation of
the airway that is determined by environmental, immu-
nological, and host genetic factors. In a subgroup of
sufferers, respiratory infections are associated with
the development of chronic disease and more frequent
inflammatory exacerbations. Recent studies suggest
that these infections are polymicrobial in nature. Fur-
thermore, there is increasing evidence that the recently
discovered asthma airway microbiota may play a critical
role in pathophysiological processes associated with
the disease. Here, we discuss the current data regarding
a possible role for infection in chronic asthma with a
particular focus on the role bacteria may play. We dis-
cuss recent advances that are beginning to elucidate the
complex relations between the microbiota and the im-
mune response in asthma patients. We also highlight the
clinical implications of these recent findings in regards
to the development of novel therapeutic strategies.
The human microbiome and its interaction with the
host
Medical and hygiene advances over the past 150 years, such
as sanitation measures, vaccines, and antibiotics, have
helped arm the fight against infectious microorganisms,
curbing infant mortality and greatly increasing life expec-
tancy. However, in recent years, it has become clear that
humans have, during the course of their evolution, devel-
oped an essential symbiotic relation with microorganisms
and this is redefining the way we view infectious disease
[1]. It is now understood that we are host to a vast number of
bacterial, fungal, viral, and eukaryotic cohabiters termed
the microbiota. In the simplest terms, the microbiota can be
defined as the microbes associated with a particular envi-
ronmental niche. Although the term microbiota has been
used for decades, clinical and scientific interest in human-
associated microbiota is more recent and has been further
stimulated by projects like the Human Microbiome Project
or sub-projects like the gut microbiome project MetaHIT.
These studies utilizing advanced molecular techniques have
generated unprecedented insight into the complexity and0966-842X/
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humans. It is clear that these microbial communities, par-
ticularly in the gut, play a key role in the protection from
pathogenic organisms and the development and mainte-
nance of immune responses. The study of the role of the
gut microbiota in modern diseases such as asthma, obesity,
juvenile diabetes, and specific cancers has revealed that
perturbations to microbial communities have a profound
effect on disease development and treatment response [1–3].
Technological advances have resulted in the advent of
high-resolution molecular investigations into the airway
microbiota in pulmonary health and/or disease. Given that
the lungs represent one of the largest interfaces between
the human host and the external environment, being
exposed to >8000 l of inhaled air each day [4], it is
unsurprising that a direct connection between aberrant
microbial colonization of the airways has been shown to
contribute to the development of chronic inflammatory
diseases such as chronic obstructive pulmonary disease
(COPD) and cystic fibrosis (CF) [5].
Until recently, the understanding of the role bacteria
play in asthma, another chronic lower airway disease, has
lagged behind its counterparts. However, clinicians and
researchers have begun to benefit from this deeper under-
standing to re-evaluate and redirect efforts to understand
the relations between asthma and microbial colonization
[5]. This has been stimulated by the fact that >300 million
people worldwide suffer from this disease, which results in
an economic burden of >$80 billion per year in the US
alone.
In this review, we discuss recent studies that have shed
light on the association of microorganisms with asthma
and the potential interactions between the airway micro-
biota and the immune system. We also discuss how a
deeper understanding of the microbiota within the asth-
matic airway may provide potential therapeutic avenues.
The asthma airway and associated microbes
Specific microorganisms and asthma disease
development
The US Department of Health and Human Services defines
asthma as ‘an inflammatory disease of the airways with
generally reversible air flow obstruction and airway hyper-
responsiveness causing episodic respiratory symptoms’,
in which many cells and cellular elements play a role
[6]. The chronic inflammation is associated with airway
hyper-responsiveness and leads to recurrent episodes of
exacerbation marked by wheezing, breathlessness, chest
tightness, and coughing [7]. Historically, the contribution
Box 1. Fungus in asthma
Culturing of fungi from airway samples is challenging due to slow
growth, specific media requirements, and the lack of quantitative
methods, which is due in part to filamentous morphologies [56–58].
Taken together, this has made it difficult to describe fungal species
and their relative burdens in respiratory disease.
Although the fungal microbiota of the asthmatic respiratory tract
has not been well characterized to date, there is evidence that specific
fungal species can play a part in the clinical progression of disease
[59]. Fungi can cause problems in the airways of asthma patients in
two ways: by acting as allergens or as pathogens causing infection,
with many fungi being able to do both and often concurrently.
It is well documented that the spores of several filamentous species
within the genera of Aspergillus, Alternaria, Cladosporius, Penicil-
lium, and Didymella (phylum Ascomycota) may act as allergens and
initiate asthma development in atopic individuals. Importantly, fungal
infection and exposure have already been linked to several clinical
consequences in asthmatics including deterioration of lung function,
increased hospital admission, and even mortality. One of the most
documented fungal infections observed in asthmatics is allergic
bronchopulmonary aspergillosis (ABPA), caused by colonization of
the lower respiratory tract with Aspergillus spp. In this situation, the
fungus acts as both a source of allergen and as a pathogen [60]. ABPA
presents itself by a range of clinical features including asthma
exacerbation, recurrent pulmonary infiltrates, elevated total serum
IgE, elevated Aspergillus-fumigatus-specific IgE or IgG, central
bronchiectasis, eosinophilia, and mucous plug production. Further-
more, ABPA is difficult to predict given that allergens produced by
A. fumigatus are diverse in nature and the dormant spores can evade
host defense mechanisms until conditions are suitable for germina-
tion [60]. Fungi have also been associated with severe asthma termed
‘severe asthma with fungal sensitization’ (SAFS) [61]. SAFS is
diagnosed by the presence of severe asthma, fungal sensitization,
and the absence of ABPA. Because of the paucity of data and
ambiguity in diagnostic criteria, SAFS is currently classed as a
diagnosis of exclusion rather than a specific entity.
Recent studies have suggested the possible benefit of antifungal
therapy in the treatment of asthmatics, with clear improvements
seen in lung function, even when fungal species have not been
cultured or detected from airway secretions [56]. Although little is
known of the airway fungal community in the pathogenesis of
asthma, these observations suggest that rigorous study should be
undertaken. This is even more important given recent studies
highlighting the complexity of fungal communities found in the oral
cavity of healthy individuals [59], the lower airways of CF, and in
COPD patients [56–58,62] using pan-fungal primer amplification
followed by pyrosequencing. These landmark studies provide the
initial standard for studying the fungal microbiota along the
respiratory tract. Taken together, it is clear that future examination
of the fungal microbiota along the respiratory tract in relation to
asthma inflammation and phenotypes could be of great interest.
Further studies will be required to characterize the impact that fungal
colonization has on the bacterial communities associated with the
asthma airway and the potential cross-kingdom interactions that
may occur.
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investigated using: (i) traditional culture-dependent
approaches to sample the airway; (ii) serological testing
to identify microbe specific antibodies in the serum; and
(iii) by species-targeted PCR (7). The importance of viral
infections as a source of asthma exacerbation and chronic
inflammation of the airways in children and adults is well
demonstrated [8,9]. The potential contribution of fungal
infection to asthma is less well understood (Box 1), and in
the case of bacterial infections, it is now felt that they can
contribute to the development of stable asthma and acute
exacerbations [10].
Despite the lack of definitive evidence, many controlled
clinical studies have demonstrated an association between
chronic stable asthma and bacteria [11–13], as infected
subjects were found to have elevated markers of inflam-
mation, increased severity of obstruction identified by
FEV1 (forced expiratory volume in one second), higher
daytime symptom score, and required high doses of inhaled
corticosteroids in comparison with noninfected controls. A
strong connection between acute exacerbations of asthma
and infection with Chlamydia pneumoniae and/or Myco-
plasma pneumoniae has also been reported [14], however,
there is insufficient data to allow for definite conclusions
about the role of such bacteria in late asthma development
[15].
Evidence is also available suggesting that exposure to
Staphylococcus aureus and/or its enterotoxins function as
an environmental risk factor for the development and
severity of asthma [16]. The locally or systemically re-
leased enterotoxins show superantigen activity and may
provoke eosinophilic stimulation leading to deterioration
of upper and lower respiratory tract atopic diseases
[16]. Specific antibodies against S. aureus enterotoxins
are more likely to be found in patients with asthma [16].Other respiratory bacteria such as Haemophilus influ-
enzae, Moraxella catarrhalis and Streptococcus pneumo-
niae have been shown to cause severe persistent wheeze in
children [17]. It was also found that neonates colonized in
the pharyngeal region are under increased risk for recur-
rent wheeze and asthma within the first 5 years of life
[17]. Particularly evident is the association of these patho-
gens with a subset of stable asthma, known as neutrophilic
asthma, where inflammation is primarily mediated by
neutrophils and less by eosinophils. H. influenzae was
isolated from the airways of patients with neutrophilic
asthma, and infection-induced inflammation [17].
Overall, this work has shown that acute respiratory
infections by specific bacteria trigger asthma exacerba-
tions through colonization or infection of the airway. How-
ever, it is still unclear and much argued whether these
single bacterial infections are true causative agents of
asthma exacerbation or act as markers for an increased
risk of asthma onset [5]. Furthermore, it is not clear what
role changes to airway architecture as a result of infection-
related damage may impinge upon the future development
of airway disease and the susceptibility to future infection.
The interpretation of these observations has become even
more complex in light of the revelation that the airways,
that were once assumed to be sterile, have a diversity
of microorganisms associated with them in asthmatic
patients.
Microbiota associated with the asthmatic airways
As discussed above, the role of microbial infection in
asthma pathogenesis remains unclear. However, the
developments in defining the human microbiota have
demonstrated that the composition of bacterial communi-
ties colonizing mucosal surfaces, rather than simply the
presence of individual species, can be important in defining409
Box 2. Characterizing the airway microbiota
Culture-dependent approaches have proved useful clinical tools in
the detection and characterization of specific microbes present in the
respiratory tract, which are responsible for infection [63]. Despite
limitations, these methods have been crucial for studying the function
of community members. However, the selectivity of culture media
and the fastidious nature of many microbes have resulted in many
important microbiota members being overlooked. In recent years,
application of culture-independent methods such as microarray
hybridization and DNA sequencing technologies has given greater
detail and information regarding airway-associated microbial com-
munities [50]. These approaches as well as determining identity and
abundance of the microbiota present can provide the researcher with
information concerning richness, evenness, and dominance. These
measures can in some cases be clinically edifying.
Studying the microbiota of the airways is considered far more
problematic than the gut due to the lower burden of biological
material and the risk of contamination from the upper airway during
sampling. Therefore, it is proposed that lower and upper respiratory
samples are obtained from each patient. Several materials that are
collected routinely by scientists from the respiratory tract include
sputum, bronchial brushings and BAL. Sputum is obtained by
induced coughing in subjects that results in the expectoration of
mucus from the lower airways. Sputum is a useful material because
it contains immune system components as well as host and
bacterial products, including RNA, which can be used to infer the
functional properties of communities. Bronchial brushings are
obtained by passing a protected bronchoscopy cytology brush
down the endotracheal tube until resistance is felt. Resistance
indicates that the brush has reached the end of the trachea; at this
point the brush is extended beyond the tip of the bronchoscope
and past the end of the protective sheath and moved back and forth
on the surface of the airway mucosa to collect the sample. The
brush is then retracted into the sheath before being retracted
through the bronchoscope to minimize contamination of the lower
airway sample. BAL involves a bronchoscope being passed through
the endotracheal tube and into the bronchus. A saline solution is
then delivered through the bronchoscope and aspirated back up
into a container.
Recently, Rogers and colleagues proposed several criteria that
should be considered when determining the microbiota of the
airway [49]. These included the following. (i) Respiratory material
collection can be done in several ways for microbiota studies.
Regardless of the material collected, it is important to consider the
ease, safety, reproducibility, and the potential for contamination. (ii)
Sample heterogeneity is also an important consideration if the
samples are collected spatially and temporally. This depends on the
research question being addressed. (iii) Nucleic acid extraction
becomes paramount once sample material has been collected.
Several studies have examined the importance of deploying
stringent extraction procedures. Most have illustrated the ease at
which distortion can creep into microbiota profiles due to poor,
inconsistent or less than rigorous nucleic acid extraction. (iv)
Methods for generating microbiota profiles are commonly carried
out using generation of 16S rRNA clone libraries, terminal RFLP
analysis, microarray hybridization, 16S rRNA phylogenetic micro-
array analysis, or deep sequencing of 16S rRNA amplicon pools.
Although the choice of method deployed typically depends on the
researchers budget and time required, ideally, this choice should
be driven by the primary hypothesis to be addressed.(v) Analyzing
the resulting data in an informed and relevant manner is imperative.
Although there are numerous methods for data analysis available,
the processing should take into account the potential for spurious
signals generated by the profiling method, the potential for
contamination during the processing of the samples, and the
potential of imperfect taxa identification.
These recently highlighted criteria for assessment of airway
microbiota are rather time-consuming and the research community
has called for greater standardization and documentation of micro-
biota profiling methods, particularly regarding work aimed at gaining
clinical insight into respiratory disease.
Review Trends in Microbiology July 2015, Vol. 23, No. 7states of health or disease. Researchers have been utilizing
new high-resolution microbial profiling methods to de-
scribe the microbial composition of the asthmatic lung
(Box 2). Results from these studies in the past 5 years
indicate that the composition of the bacterial microbiota
detected from the airways of asthmatic patients differs in
comparison to those of healthy subjects, although there are
variations in the details of these findings [5,12,18], likely
reflecting the heterogeneity across asthmatic populations.
One of the landmark studies that utilized 16S rRNA
clone libraries to examine the respiratory samples from
adults and children with asthma found the lung bacterial
community to contain members of the Proteobacteria phy-
lum, in particular, Haemophilus spp., Neisseria spp., and
Moraxella spp. Although the resolution of this approach is
lower than many newer profiling methods, it did find that
these strains were more commonly found in asthmatics
than the healthy controls tested [19]. A subsequent study
of bronchial brushings from 75 patients with mild to
moderate asthma, using a higher-resolution 16S rRNA
phylogenetic microarray platform to assay the airway
microbiome, found 100 bacterial taxa that were strongly
correlated to airway hyper-responsiveness [11]. This study
like others found that members of the phylum Proteobac-
teria were significantly enriched in asthmatics and also
included families of potential pathogenic bacteria such as
Haemophilus and Streptococcus spp. More recently, an
examination of induced sputum samples from treatment-
resistant severe asthmatics during a non-exacerbation410phase of their disease using lower-resolution terminal
restriction fragment length polymorphism (T-RFLP) anal-
ysis revealed again that patient airway colonization was
predominantly with Haemophilus spp., Streptococcus spp.,
or M. catarrhalis [20].
Studies involving larger numbers of asthmatic patients
have observed relations between the clinical outcome and
airway microbiota diversity [11]. One of the most compre-
hensive studies, which examined the microbiota profile of
65 adults who suffered from suboptimally controlled asth-
ma showed positive correlation between the abundance of
specific airway microbiome members (Comamonadaceae,
Sphingomonadaceae, and Oxalobacteraceae) and the de-
gree of airway hyperactivity. Although correlation is not
causality, it suggests that the presence of specific microbial
species in the lower airway is associated with the degree of
bronchial hyper-responsiveness, a key feature of asthma
[11]. More recently, in patients with severe asthma, rela-
tions have been reported between airway microbiota and
body mass fluctuations [11], as well as neutrophils and
interleukin (IL)-8 accumulation in sputum [18]. These
relations may influence the type or degree of airway in-
flammation seen in certain patients and may contribute to
the complexity in defining phenotypes within asthma.
Although all these studies describe extensive diversity
in the airways of examined asthmatics, it is important to
note that little consideration was given to the impact that
patient treatments such as inhaled corticosteroids, bronch-
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Figure 1. Microorganisms involved in asthma airway colonization. A cross-section of the human lower respiratory tract is depicted, showing sites of infection for different
microorganisms and the effects that they have on airway function. The phylogenetic ring depicts the percentage abundance of bacterial phyla identified in various
biological samples taken from the airways of asthma patients (Information used to compile figure was reported in [12,19]. Inner ring (bronchoscopic brushing samples);
middle ring (BAL samples), and outer ring (induced sputum samples). Abbreviation: BAL, bronchoalveolar lavage.
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carried out using 16S rRNA profiling of DNA extracted
from bronchoalveolar lavage (BAL) fluid to compare the
airway microbiota of corticosteroid-resistant and cortico-
steroid-sensitive asthmatics [21]. Although, this work
failed to highlight changes in the microbial community
that were consistently associated with steroid-resistant
asthma, the work did go on to define the influence of
Haemophilus parainfluenzae on the expression of cortico-
steroid-regulated genes of BAL macrophages in an in
vitro co-culture model. It concluded that co-culture with
H. parainfluenzae as opposed to the commensal genus
Prevotella resulted in inhibition of the steroid response.
Another longitudinal study was conducted to measure the
impact of the antibiotic azithromycin on the airway micro-
biota of five adult patients with asthma [22]. The result
was the reduction in the representation of the Haemophi-
lus, Pseudomonas, and Staphylococcus genera within the
community, which coincided, with establishment of Anae-
rococcus as the most dominant members of the community.
Despite limitations of small sample sizes, potential
biases in sampling methods, and unanswered questions
regarding treatment influence, the overall findingsbetween most studies are generally consistent and provide
further evidence that airway microbiota diversity associ-
ated with asthma is likely due to the disease itself
(Figure 1). The other possibility is that the microbiome
drives disease and/or features of the disease such as steroid
non-responsiveness. Most importantly, now that these
communities are being understood in greater detail, there
is a pressing need to explore the mechanistic link between
microbial communality and asthma development/severity,
with research into the interaction between the microbiota
and mucosal immunity being vitally important.
The potential contribution of airway microbiota to
asthma subtypes and the immune response
One of the classic features of asthma is the presence of
specific immune cells in the airway. Simpson and collea-
gues [23] have used this to describe four inflammatory
subtypes of asthma based on the immune cell profile of
sputum taken from patients (Table 1). These subtypes
include eosinophilic (eosinophils >3%), neutrophilic
(neutrophils >61%), mixed granulocytic (increased eosin-
ophils and neutrophils), and paucigranulocytic asthma
(normal levels of both of these specific immune cell types).411
Table 1. Asthma subtypes and molecular characteristics
Asthma subtypes Molecular pathology
Eosinophilic Eosinophils >3% in sputum taken from
the airway
Can be associated with high or low Th2
Stimulation of IL-5 and other various
cytokines
Associated with steroid responsiveness
Thickening of the basement membrane
Neutrophilic Neutrophils >61% in sputum taken from
the airway
Can be associated with high Th17
Stimulation of IL-8
Associated with steroid non-responsiveness
Normal basement membrane thickness
Mixed-granulocytic Increased eosinophils and neutrophils,
cytokine stimulation
Paucigranulocytic Normal levels of eosinophils and neutrophils,
cytokine stimulation
Review Trends in Microbiology July 2015, Vol. 23, No. 7Numerous researchers and clinicians have used these
asthma subtypes for classification. Recent work has begun
to elucidate the association between lung microbiota func-
tion and immune response in eosinophilic and neutrophilic
asthma subtypes that we describe below (Figure 2).
Eosinophilic asthma
Eosinophil accumulation in the airway (eosinophilia) is
associated with thickening of the basement membrane
and is often responsive to corticosteroid treatment
[24]. This eosinophilia is most commonly associated with
allergic or atopic asthma and accounts for the majority of
disease. The generally held view for allergic asthma is that
it is driven by sensitization to an allergen that is followed
by subsequent challenge. The result of this multifactorial
event is the activation of T cells and the conversion to a T
helper (Th)2 type immune response. Th2-associated cyto-
kines IL-4, IL-5, IL-9, and IL-13 promote the presence of
eosinophils in the airway and in turn lead to an increase in
IgE levels in the blood. Additionally, IgE levels are known
to be elevated in the respiratory tract of eosinophilic
asthmatics in response to antigens from many common
airway microbial colonizers [25]. IgE binds to IgE receptors
on the surface of mast cells and becomes crosslinked upon
binding of allergens resulting in mast cell degranulation.
The result of mast cell degranulation is the release of
preformed mediators of inflammation such as histamine,
tumor necrosis factor (TNF)-a, IL-13, and IL-4. Ultimately,
this results in enhanced vascular permeability and the
recruitment of inflammatory cells to the airway. The link
between Th2 responses and allergic inflammation was412initially established in mice and subsequently Th2 cyto-
kines were then detected in asthmatic patients. Tran-
scripts of IL-4, IL-5, and IL-13 in patient sputum can be
detected and quantified by PCR and can be used as bio-
markers of a ‘Th2-high’ response [26]. Gene expression
microarrays demonstrated that monitoring of CLCA1,
periostin, and serpinB2 expression could be used as mar-
kers to estimate and monitor a Th2 response [27].
Recent studies have begun to challenge the long held
view that allergic reactions represent unintentional im-
mune responses [28]. Instead it is proposed that allergic
host defenses have evolved as protection against harmful
substances such as irritants, noxious chemicals, and for-
eign toxins. The extent to which microbial derived pro-
ducts, toxins, or components present in the airway
contribute to allergic responses remains a largely unex-
plored but exciting question. This suggests that the ability
to cause tissue damage may be a common feature of
substances that trigger appropriate allergic responses
regardless of their source [28]. Little is known about the
contribution of the airway microbiota to such mechanisms
but clues are emerging that highlight the need for further
investigation. For example, it is known that group 2 innate
lymphoid cells (ILC2s) can be activated directly by
microbes acting on Toll-like receptors (TLRs) [29,30].
Recent work in mice has led to the discovery that ILC2s
can release Th2-type cytokines in response to epithelial
damage and this may be a potential mechanism by which
damage caused by members of the airway microbiota could
elicit an asthmatic response [31–33].
It has also been shown that low levels of microbe-
derived lipopolysaccharide (LPS) sensed through TLR4
can enhance the Th2 response [34]; responses are con-
text-dependent and LPS also induces Th1 responses. This
again indicates that the airway microbiota has the poten-
tial to modulate the allergic response where different
manifestations may be heavily dependent on the environ-
mental context. Work with neonatal mice showed that
manipulating the lung microbiota composition provided
a potential protective role in allergic responses [35]. The
work demonstrated that immediately after birth the air-
way mucosa was primed for a strong response to allergen
challenge. However, 2 weeks postpartum the bacterial load
in the lungs increased and there was a change in composi-
tion from Gammaproteobacteria and Firmicute dominance
to the establishment of Bacteroidetes. This shift in com-
munity was associated with the inducement of the Helios T
regulatory cell subset and decreased aeroallergen respon-
siveness. Future work should further elucidate the inter-
action between specific microbes and components of the
immune system contributing to allergy.
Neutrophilic asthma
Neutrophils are one of the earliest immune cells recruited
to sites of damage and infection of the airway. Many lung
diseases such as COPD and CF are associated with neu-
trophilic inflammation [36,37]. Asthma is no exception
with 30% of patients suffering from neutrophilic asthma.
This is characterized by substantial and sustained in-
crease in airway neutrophils (neutrophilia), which is linked
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Figure 2. Bacterial and viral infections of the airways activate immune and structural cells, promoting inflammation and influencing responses to other pathogens,
allergens and pollution. The schematic depicts potential triggers and innate immune response of eosinophilic (Th2 dependent) and neutrophlic (non-Th2 dependent)
asthma. Left panel: Environmental allergens such as pollen and mold spores can trigger Th2 asthma. Th2 immune processes begin with the development of Th2 cells and
their production of the cytokines IL-4, IL-5, and IL-13. These cytokines stimulate allergic and eosinophilic inflammation as well as epithelial and smooth-muscle changes that
contribute to asthma pathobiology. Right panel: Cigarette smoke, pollutants and the PAMPs from airway microbes including LPS from bacteria or ssRNA from respiratory
viruses can potentially trigger non-Th2 asthma. There is a range of factors that can contribute to the development of non-Th2 asthma. These factors include infection-related
elements, Th1 and Th17 immunity, non-Th2 associated smooth-muscle changes and the development of neutrophlic inflammation. Abbreviations: APC, antigen-presenting
cell; CRTH2, chemoattractant receptor-homologous molecule expressed on Th2 cells; dsRNA, double-stranded RNA; PGD2, prostaglandin D2. IFN, interferon; GRO, growth-
regulated oncogene; IL, interleukin; LPS, lipopolysaccharide; PAMP, pathogen associated molecular pattern; ssRNA, single-stranded RNA; Th, T helper; TLR, Toll-like
receptor.
Review Trends in Microbiology July 2015, Vol. 23, No. 7Although eosinophilic asthma has been connected with
the Th2 response, neutrophilic asthma is believed to be a
non-Th2 immune response [38]. It is recognized that this
potent innate immune response can be stimulated by
Gram-negative and Gram-positive bacteria and their
products, including endotoxins, with cell wall and outer
membrane components all potentially acting as pathogen-
associated molecular patterns (PAMPs), which are recog-
nized by TLRs, G protein-coupled receptors (GPCRs),
CD14, and collectins. Activation of TLRs leads to inflam-
matory cascades that result in production of the proin-
flammatory cytokines IL-8 [also known as chemokine
CXC ligand (CXCL)8], IL-1, and TNF-a, generating a shift
toward a Th1 and Th17 response, extensive neutrophil
recruitment, and a change in inflammatory cell differential
profile. Consistent with this, there is evidence in treat-
ment-resistant severe asthma of increased TNF-a gene
and protein expression within the airways compared to
that in mild asthma [39]. Some members of the GPCR
family transduce signals through cytoplasmic G proteins
to cytoskeletal proteins controlling the movement of leu-
kocytes. The GPCRs FPR1 and FPR2 (human formyl pep-
tide receptor 1 and 2) as well as GPCRs 41 and 43 (GPR41
and GPR43) are all expressed by neutrophils and can
detect PAMPs. Activation of these receptors results in
the recruitment of neutrophils from the bloodstream tosites of infection, activation of the oxidative burst and IL-8
release [40].
An intriguing hypothesis that is gaining notoriety is
that sustained microbial colonization of the airway could
promote the neutrophilia observed in asthma. Studies lend
strength to this argument by showing that S. aureus,
M. catarrhalis, and H. influenzae are detected in sputum
from neutrophilic and stable severe asthmatics [13,41].
Furthermore, strong associations have been revealed be-
tween increased bacterial load and higher concentrations
of airway neutrophils and the neutrophil chemoattractant
IL-8. Also linked to neutrophilic asthmatics is the resis-
tance to corticosteroid treatment. Although only a small
number of studies have been carried out, it appears that
patients resistant to corticosteroid treatment are predomi-
nantly colonized by the same communities of bacteria
as neutrophilic asthmatics are. Work investigating the
influence of H. parainfluenzae on the expression of corti-
costeroid-regulated genes of BAL macrophages in an
in vitro co-culture model concluded that the presence of
H. parainfluenzae resulted in inhibition of the steroid
response as opposed to the presence of commensal mem-
bers of the genus Prevotella [21].
A recent study examining bronchial biopsies implicated
IL-17 in causing substantial neutrophil recruitment in
the airways suggesting that the neutrophilic asthmatic413
Review Trends in Microbiology July 2015, Vol. 23, No. 7response is more complex than believed [42]. IL-17 drives
Th17 responses, which provide protection from infection at
mucosal surfaces. Further work provides evidence that the
Th17 lineage of T cells has a role in controlling pulmonary
bacterial infections and have already been implicated in
those caused by Klebsiella pneumoniae infection [43]. Fur-
thermore, Th17 cytokines are associated with moderate
and severe asthma with IL-17A, IL-17F, and IL-22, func-
tioning to increase smooth muscle mass, mucus produc-
tion, and the indirect recruitment of neutrophils to the
airways by inducing the release of the chemokines CXCL1
and IL-8 from epithelial cells [44]. It should be noted that
recent work looking at bronchial biopsies failed to find an
association with IL-17A/IL-17F and neutrophilia [42]. In-
terestingly, the cytokine profile and presence of microbial
products at a site of infection can determine the lifespan of
neutrophils. Activation of pattern recognition receptors
(PRRs) on the surface of neutrophils such as TLR 1, 2, 4,
5, 6, 8, and 9 have been shown to enhance neutrophil
survival where nuclear factor (NF)-kB and mitogen-acti-
vated protein kinase (MAPK) signaling is important
[45]. The pattern recognition function of neutrophils
may represent an important pathway directly linking
the detection of lung microbiota members and neutrophil
survival in the airway.
Although investigation into the microbial contributions
to these various subtypes of asthma are in the initial
stages, they provide confidence that research should be
undertaken to link microbial burden and community com-
position with specific immune responses. The categoriza-
tion of asthmatics based on the immune cell profile of the
sputum is an invaluable tool that should be utilized to
elucidate the functional properties of the lung microbiota.
However, there are many questions regarding the stability
of these inflammatory phenotypes over time, especially in
children with asthma, and more longitudinal studies are
required. This variability may be partly explained by
variations in environmental exposure over time. Other
complementary approaches are required to understand
these complex immunopathologies. A recent study looking
at differential expression of host genes found a six-gene
signature that could be used as a biomarker to distinguish
different inflammatory subtypes [39]. In the future, these
clinically measurable outputs should be combined with
sputum metabolomics data, patient genetics, and patient
information (including history of infection) to better define
asthma endotypes, as outlined in a recent review [46], and
the contribution of the lung microbiota to each of these.
Ultimately, this will lead to the replacement of asthma as
an umbrella term for a range of inter-related but distinct
conditions [38].
Asthma treatment in the light of improved
understanding of the associated airway microbiota
Many research groups have begun to devise and test
methods to exploit and convert this newfound knowledge
of the microbiota of the respiratory tract into improved
or even new treatment strategies for asthma and other
inflammation-based diseases. Below, we discuss some of
the approaches that have been proposed in potentially
improving treatment of asthma.414Predication of onset of asthma exacerbation
The asthma severity correlates with microbiota dysfunc-
tion and inflammation in the airways [47,48]. Acute
periods of exacerbation are one of the most important
causes of morbidity in asthma sufferers. Consequently,
the control of asthma has depended on the management
of inflammation. The precise triggers of exacerbation
are complex but it has become clear that the current
techniques to measure dysfunction and inflammation
in asthma patients (history, physical examination, and
spirometry) are somewhat insensitive [49]. One of the
key objectives of asthma clinicians now is to improve
the ability to accurately monitor airway inflammation
through noninvasive means. Although several inflammato-
ry-marker-based methods have been developed, such
factors are typically only elevated during the inflammato-
ry/exacerbation process, providing limited periods where
treatment intervention will be useful. Advances in our
understanding of microbiota in asthma and the rapid
diagnostic tools that are being developed in tandem now
allow the examination of these microbial communities, with
the likelihood of identifying potential microbial signatures
on which rapid diagnostic assays can be based. To date,
there is little work carried out examining if microbial
signatures can predict the onset of asthma exacerbation
[50]. However, studies that have mapped the bacterial
community structure during periods of stability and exacer-
bation in the airways of CF patients suggest this approach
may be feasible. For example, a recent study has identified
several orders of anaerobic bacteria that are more predomi-
nant in CF patient airways undergoing exacerbation
[50]. Although it is unlikely that the microorganisms colo-
nizing the CF airway are the sole contributors to exacerba-
tion, further longitudinal studies could establish if the
changes identified preceded the onset of exacerbation as
measured by clinical parameters. The identification and
deployment of microbial signatures in asthma diagnosis
is less advanced than other diseases but at this point
longitudinally collected sample sets need to be investigated
for their potential.
Immune manipulation using prebiotics, probiotics, and
other microbiological supplements
There is increasing evidence to suggest that the intestinal
microbiota, particularly during early infancy, plays a criti-
cal role in regulating immune responses [51]. Several
studies have shown that modulations of the resident gut
commensal microbiota can shape the global immune re-
sponse of the host, reducing sensitization and inflammation
[51]. Several recent studies have illustrated that microbiota
manipulation via oral prebiotics, probiotics, and other
supplementation promotes healthy gut microbiota and
reduces overt airway immune responses in asthma patients
[52,53]. Studies examining the impact of prebiotics on the
immunogenicity of asthma are summarized in Table 2.
Although data from these tests are not altogether convinc-
ing, they do give strength to the possibility of promoting
a healthy microbiota in asthmatics, which may have poten-
tial health benefits. These approaches show some merit in
treatment of other inflammation-based diseases such as
obesity and juvenile diabetes but specific work on asthmatics
Table 2. Studies since 2011 showing the varied impact of prebiotics, probiotics, and other supplements on the immunogenicity of
asthma or associated symptoms from a range of clinical trials, epidemiological studies, and murine models
Approach Objective Delivery Outcome Refs
Prebiotics
Bacteria oligosaccharides Examination of infants in the first
six months of life without clinical
evidence of allergy, both with and
without risk factors for allergic




Evidence suggested that the
prebiotic supplement added to
infant feeds potentially prevents
eczema. It was unclear whether it









The evidence is supportive of
vitamins A, D, and E; zinc; fruits and
vegetables; and a Mediterranean
diet contributing to the prevention
of asthma.
[65]
Mediterranean diet A general population of children




Mediterranean diet tended to be
associated with lower occurrence
of the asthma symptoms.
[66]
Antioxidant 2442 8-year-old children from the
Swedish birth cohort study
BAMSE.
Oral Magnesium intake seems to have a
protective effect on childhood
asthma.
[67]
Cord blood vitamin D 257 children from the Copenhagen
prospective studies on asthma in
childhood (COPSAC2000) at-risk
mother-child cohort.
Oral No association between cord blood
25(OH)-vitamin D level and
changes in lung function,
sensitization, rhinitis or eczema
were observed.
[68]
Cord blood vitamin D 158 children at age 3 years. Oral Prenatal vitamin D supplementation
in late pregnancy had a modest
effect on cord blood vitamin D level.
This study found that cord blood
vitamin D level was not associated
with decreased wheezing in
offspring at age three years.
[69]
Fish oil 420 infants considered high atopic
risk.
Oral Postnatal fish oil supplementation
improved infant n-3 status but did




Single strain or mixture of
bacterial strains – mainly
Lactobacillus rhamnosus GG (LGG)




reduces the risk of atopic
sensitization, but it does not reduce




Murine model of allergic asthma. Oral LGG had an anti-inflammatory
effect on OVA-induced airway
inflammation.
[72]
Single strain or mixture of
bacterial strains – mainly
Lactobacillus rhamnosus GG (LGG)
4866 children. Metadata assessing a
collection of delivery
methods
No evidence to support a protective
association between perinatal use
of probiotics and doctor diagnosed
asthma or childhood wheeze.
[73]
Strains of Lactobacillus or
Bifidobacterium were
mainly used





Due to the high degree of
heterogeneity in the data assess





232 families with allergic disease,





The effect of L. reuteri on
sensitization and IgE-associated
eczema in infancy did not lead to a
lower prevalence of respiratory
allergic disease in school age. Thus,
the effect of L. reuteri on the immune




171 children that completed the
intervention, 121 were assessed at
age 8–9
Oral No long-term effect of LF19 on any
diagnosed allergic disease, airway
inflammation or IgE sensitization.
[76]
Microbial products
Lipopeptide Murine model of asthma. Intraperitoneal Protection against sensitization







Infants at high risk of atopy. Oral Decreased the incidence of
potentially allergic AE (PAAE)s.
[75,78]
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Box 3. Outstanding questions
 To what extent does an altered airway microbiota effect the
development or worsening of asthma symptoms?
 Do standard treatments, such as steroids, antibiotics or inhaled
medication, contribute to the shaping of the asthma airway
microbiota and does this have implications for disease symp-
toms?
 Many microorganisms (virus, bacteria, and fungi) can coexist in
the respiratory tract of an asthmatic patient. If interplay occurs
between these organisms, what impact does it have on shaping
the inflammatory response and the response to treatment?
 How best can we classify phenotypes of asthma to determine
precisely what role the microbiota plays in the development of
disease and patient prognosis?
 Many challenges apply to modeling asthma disease. However,
with new translational models of asthmatic lung disease, can
models of microbiota interactions with the host be developed?
 Are changes in microbiota composition predictive of asthma
exacerbation or respiratory tract infection? Will this provide a
platform for preventative treatment using targeted interference
strategies and antimicrobial therapy?
 Can biotherapeutic strategies such as the use of prebiotics or
probiotics be developed to counteract microbiota dysbiosis in
asthmatic patients and could this have a knock-on effect on care?
Review Trends in Microbiology July 2015, Vol. 23, No. 7is still required to surmount the scientific, health, and
regulatory concerns.
Tailored antimicrobial or vaccine therapy of specific
microbiota community members
As discussed earlier, airway infections by specific micro-
biota or bacteria may induce, augment, or potentially even
modify the predominant type of airway inflammation
seen in asthma. It has been proposed that more focused
antibiotic or vaccine therapies based on comprehensive
characterization of the microbiota present in the airway
could inform the use of antimicrobials that target specific
microbiota in asthmatics [49,54]. Conversely, microbiome-
targeted treatment approaches could be interpreted from
the perspective of how to promote a more functionally
balanced airway microbiome, such that pathogenic micro-
biota are not able to exert dominant effects. Thus, an
understanding of microbiota that are negatively associated
with features of asthma could be useful toward developing
approaches to promote these microbiota, or specific func-
tions they express that counteract detrimental inflamma-
tory processes. These approaches have been studied and
highlighted more in the gut microbiome literature but
suggest that the approach may be feasible in the treatment
of asthma [55].
Although still in their infancy, these potential new
approaches for the treatment of asthma, used in combina-
tion with other therapeutic measures including vaccines
and steroid treatment, could improve, alleviate, and treat
asthma symptoms. Many obstacles exist to the use of these
approaches but key among these is the complex heteroge-
neity of asthma as a disease and the variation in micro-
biome composition observed across this patient population.
As discussed above, this heterogeneity of asthma reflects
different underlying clinical characteristics, biology, and
genetics, which can all make different contributions to
shaping microbial diversity found in the asthmatic airway.
Therefore, it is becoming paramount that the phenotypes
or subtypes of asthma are more clearly defined to deter-
mine specifically when the microbiota plays an important
role in asthma. As touched on above, a selection of schemes
have been proposed to classify asthma phenotypes. It will
become important that a stringent and more feasible clas-
sification approach is adopted in order to enable more
focused development of microbiota driven treatment in
asthma.
Concluding remarks
It is now clear that high-resolution microbiota sequencing
efforts and translational models of lung disease are pro-
viding new insight into the roles of microorganisms in
asthma pathogenesis and exacerbation. Bacteria clearly
have roles to play in the disease progress and clinical
outcome of asthma but also appear, in certain cases, to
play protective functions. There is also vast experimental
and clinical evidence that asthma can be viewed as a
chronic inflammatory disease that can be initiated and
modulated by the airway microbiota. These interactions
with the host immune system can involve commensal
bacteria as well as pathogens that most likely mediate a
range of molecular mechanisms. It may be that increases in416asthma prevalence worldwide are due in part to a changing
relation with microbes in the lower respiratory tract. More
research is needed to provide better mechanistic insights
into interactions between the airway microbiota and host
immune response, as well as address several outstanding
questions in the field (Box 3). Understanding the molecular
basis and biological effect the airway microbiota has on the
host immune response may lead to the discovery of micro-
bial or immunological targets that are amenable to manip-
ulation for the development of new treatments.
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